Velin Stratev, Diana Petkova, Valentina Dimitrova and Jordan Petev
2. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013;1:73-83
3. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008;102:1248-56
4. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455-68.
5. Divo M, Cote C, de Torres JP
OSAS (obstructive sleep apnoea syndrome) is the most common type of sleep apnoea, characterised by obstruction of the upper airways during sleep, causing the absence or reduction of airflow, although there is respiratory muscular activity. It contributes to the occurrence of multiple complications such as hypertension, obesity, diabetes mellitus, cardiac and cerebral pathology, metabolic damage. The objective of this study was to evaluate the major comorbidities associated with OSAS in a group of 101 clinically diagnosed and polysomnographic patients with OSAS at “Marius Nasta” Institute in Bucharest during 2014-2015. The obtained results revealed a very high prevalence of ENT disorders, hypertension, dyslipidaemia and gastroesophageal reflux. Also, among these patients, there was an increased incidence of rhythm disorders (17.8%), such as RBB, ESSV, FiA, but also of ischaemic heart disease (16.83%).
Respir Crit Care Med 1998; 158: 1730-8.
3. Almagro P, López Garcia F, Gabrera FG, Montero L, Morchón D, Díez J, et al . Co-morbidity and gender-related differences in patients hospitalized for COPD. Respir Med 2010; 104: 253-9.
4. Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC, et al . Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-55.
5. Buffels J, Degryse J, Liistro G. Diagnostic certainty, co-morbidity and medication in a primary care population with
Ciprian Todea-Moga, Radu Boja, Daniel Porav-Hodade, Adrian Maier, Oliver Vida and Orsolya Mártha
Introduction: The objective of this study is to evaluate the efficacy and safety of PCNL as a method of treatment of renal stones in elderly patients.
Material and method: This was a retrospective study conducted over a period of 5 years in the Clinic of Urology, where we analyzed the surgical protocols and case reports of 56 patients who underwent PCNL intervention.
Results: The incidence of urolithiasis was higher in females 69.6% (n = 39) than in males 30.4% (n = 17). Comorbidities included hypertension (48.2%), chronic ischemic cardiopathy (28.6%), chronic cardiac failure (16.1%), type II diabetes (17.9%), obesity (39.3%), chronic renal failure (8.9%), chronic or recurrent urinary tract infections (30.4%), history of kidney stones (21.4%), solitary kidney surgery (1.8%), renal malformation (horseshoe kidney and renal incomplete duplication) (3.6%), urethral stricture (3.6%). Nine patients had a duble “J” catheter inserted on admission. The group of male patients presented prostate hyperplasia in 35.3% of the cases and prostate carcinoma in 5.9% of the cases.
Conclusions: PCNL is an effective and safe treatment of kidney stones in elderly patients, with a stone- free rate increased despite existing comorbidities. The presence of comorbidities requires careful preoperative evaluation. PCNL in elderly patient has similar results to those seen in younger patients.
1. Santiago JA, Bottero V, Potashkin JA. Biological and Clinical Implications of Comorbidities in Parkinson’s Disease. Front Aging Neurosci , 2017
2. Todorova A, Jenner P, Chaudhuri KJ. Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Practical Neurology 14(5): 310–322, 2014
3. Geng X, Lou H, Wang J et al. α-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am J Physiol Endocrinol Metab 300: 276–286, 2011.
4. Vidal-Martinez G, Yang B, Medrano J
Carmine Zoccali, Samar Abd ElHafeez, Evangelia Dounousi, Rossana Anastasi, Giovanni Tripepi and Francesca Mallamaci
CKD is a problem of epidemic dimension. The risk of death and cardiovascular complications in this condition is of the same order of that by myocardial infarction, which qualifies CKD as “risk equivalent”. Calculations made on the basis of the epidemiological data of the MONICA-Augsburg study and analyses of the costs of myocardial infarction in a large health insurance company in Germany show that the economic burden of cardiovascular comorbidities with CKD in this country is substantial. These estimates, which may be valid also for other large member states of the European Community, represent a call for studies looking at the cost-effectiveness of preventive interventions aimed at reducing the risk for CKD and at lowering the concerning incidence rate of death and disability due to CKD-triggered cardiovascular complications in CKD patients.
, Cirelli G, Cilione C, Coletti O, et al . Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487–92.
14. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al . Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008;178:332–8.
15. Mahishale V. Ageing world: Health care challenges. J Sci Society 2015; 42: 138–43.
16. India Tuberculosis-Diabetes Study Group
Borislav T. Dimitrov, Veronika H. Gincheva, Iva G. Simeonova, Anika I. Ivanova, Maria P. Petkova, Dimitar K. Gospodinov and Regina Komsa-Penkova
Vasc Biol. 2012;32(3):563-8.
8. Kimball A, Gladman D, Gelfand J, Gordon K, Horn E, Korman N, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations forscreening. J Am Acad Dermatol . 2008;58(6):1031-42.
9. Komsa-Penkova R, Kovacheva-Kotseva K, Angelova S, Savov A, Simeonova M. [Selected methods of DNAanalysis and clinical applications]. 1st ed. Pleven: MU-Pleven; 2004. Bulgarian.
10. Lutsey P, Prizment A, Folsom A. Psoriasis is associated withagreater risk of incident
Liliana Alexandrina Grigoriu, Ștefan Dumitrache Rujinski, Radu Gabriel Vătășescu and Miron Alexandru Bogdan
comorbidities such as cardiovascular diseases, diabetes, dyslipidemia, chronic obstructive pulmonary disease (COPD), and obesity hypoventilation syndrome. Regarding the relationship with cardiovascular diseases, OSA is an independent risk factor for systemic hypertension, congestive heart failure, myocardial ischemia, arrhythmias, stroke, and sudden cardiac death ( 6 , 7 , 8 , 9 , 10 , 11 ).
There are close relationships between body weight and OSA, and weight loss can improve the severity of the disease and the metabolic disorders observed in both OSA and obesity ( 12
Andrej Zist, Eitan Amir, Alberto F. Ocana and Bostjan Seruga
, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008; 67: 124-32.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351